Unknown

Dataset Information

0

Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome.


ABSTRACT: Glioblastoma is the most common malignant brain cancer in adults, with poor prognosis. The blood-brain barrier limits the arrival of several promising anti-glioblastoma drugs, and restricts the design of efficient therapies. Recently, by using state-of-the-art technologies, including thymidine kinase targeting system in combination with glioblastoma xenograft mouse models, it was revealed that targeting glioblastoma-derived pericytes improves chemotherapy efficiency. Strikingly, ibrutinib treatment enhances chemotherapeutic effectiveness, by targeting pericytes, improving blood-brain barrier permeability, and prolonging survival. This study identifies glioblastoma-derived pericyte as a novel target in the brain tumor microenvironment during carcinogenesis. Here, we summarize and evaluate recent advances in the understanding of pericyte's role in the glioblastoma microenvironment.

SUBMITTER: Guerra DAP 

PROVIDER: S-EPMC6238207 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5687837 | BioStudies
2013-01-01 | S-EPMC3711032 | BioStudies
2020-01-01 | S-EPMC7171590 | BioStudies
2018-01-01 | S-EPMC5782812 | BioStudies
1000-01-01 | S-EPMC4821019 | BioStudies
2019-01-01 | S-EPMC7322693 | BioStudies
2014-01-01 | S-EPMC4102477 | BioStudies
2016-01-01 | S-EPMC5031293 | BioStudies
2010-01-01 | S-EPMC3056408 | BioStudies
2010-01-01 | S-EPMC3241506 | BioStudies